QR code

Association of fibronectin 1 deregulation with tyrosine kinase inhibitor resistance in chronic myeloid leukemia

IntroductionTherapy of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) targeting the BCR::ABL1 kinase has become a paradigm for precision oncology. Despite the tremendous success of this strategy, with an overall long-term survival rate of 83%, approximately 25% of CML patients...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Lina Tiedemann, Sivahari Prasad Gorantla, Philine Ahlf, Lucie Sophie Schmidt, Christiane Pott, Merit Litterst, Vicki Waetzig, Inga Nagel, Johanna Ruemenapp, Nikolas von Bubnoff, Ingolf Cascorbi, Meike Kaehler
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Frontiers Media S.A. 2025-12-01
Reeks:Frontiers in Cell and Developmental Biology
Onderwerpen:
chronic myeloid leukemia
drug resistance
fibronectin 1
imatinib
tyrosine kinase inhibitor
Online toegang:https://www.frontiersin.org/articles/10.3389/fcell.2025.1725857/full
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items